Anticancer activity of palladium-based complexes against triple-negative breast cancer

被引：114

作者：

Vojtek, Martin ^{[1
]}

Marques, Maria P. M. ^{[2
,3
]}

Ferreira, Isabel M. P. L. V. O. ^{[4
]}

Mota-Filipe, Helder ^{[5
]}

Diniz, Carmen ^{[1
]}

机构：

[1] Univ Porto, Fac Pharm, Dept Drug Sci, LAQV,REQUIMTE,Lab Pharmacol, Porto, Portugal

[2] Univ Coimbra, Dept Chem, Unidade I&D Quim Fis Mol, Coimbra, Portugal

[3] Univ Coimbra, Dept Life Sci, Coimbra, Portugal

[4] Univ Porto, Fac Pharm, Dept Chem Sci, LAQV,REQUIMTE,Lab Bromatol & Hydrol, Porto, Portugal

[5] Univ Lisbon, Fac Pharm, iMed ULisboa, Lisbon, Portugal

来源：

DRUG DISCOVERY TODAY | 2019年 / 24卷 / 04期

关键词：

BENZOPHENONE IMINES SYNTHESIS; CELLS IN-VITRO; ANTITUMOR-ACTIVITY; SACCHARINATE COMPLEX; CYTOTOXIC ACTIVITY; DNA-BINDING; MOLECULAR-MECHANISMS; PD(II) COMPLEXES; MUTANT P53; APOPTOSIS;

D O I：

10.1016/j.drudis.2019.02.012

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Treatment of triple-negative breast carcinoma (TNBC) remains an unmet medical need with no targeted therapy available to date. Accounting for 10-30% of all human breast cancer tumors, this mammary carcinoma subtype has a particularly poor prognosis owing to its high metastatic potential, aggressive biology and limited pharmacological treatment options. Platinum chemotherapeutics are the mainstay therapy in patients with TNBC but their clinical use is limited by severe toxicity and acquired resistance. Palladium-based complexes are appealing alternative metal-based drugs because of significant similarities regarding structure and coordination chemistry with the platinum agents. This review summarizes the knowledge gathered so far on 121 Pd(II) complexes, emphasizing their anticancer activity and putative pharmacological targets toward TNBC.

引用

页码：1044 / 1058

页数：15

共 50 条

[21] Triple-negative breast cancer
Aschenbrenner, Diane S.
AMERICAN JOURNAL OF NURSING, 2020, 120 (08) : 22 - 23
[22] Triple-negative breast cancer
Reinaldo D Chacón
María V Costanzo
Breast Cancer Research, 12
[23] A novel (+)-dehydroabietylamine derivative shows activity against triple-negative breast cancer cells
Gautam, Lekh Nath Sharma
Ling, Taotao
Rivas, Fatima
CANCER RESEARCH, 2016, 76
[24] Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models
Kurt Schönfeld
Peter Herbener
Chantal Zuber
Thomas Häder
Katrin Bernöster
Christoph Uherek
Jörg Schüttrumpf
Pharmaceutical Research, 2018, 35
[25] Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models
Schoenfeld, Kurt
Herbener, Peter
Zuber, Chantal
Haeder, Thomas
Bernoester, Katrin
Uherek, Christoph
Schuettrumpf, Joerg
PHARMACEUTICAL RESEARCH, 2018, 35 (06)
[26] Synthesis and antiproliferative activity of hydroxyferrocifen hybrids against triple-negative breast cancer cells
Cazares-Marinero, Jose de Jesus
Top, Siden
Vessieres, Anne
Jaouen, Gerard
DALTON TRANSACTIONS, 2014, 43 (02) : 817 - 830
[27] Cytotoxic activity of Cape Fynbos against triple-negative breast cancer cell line
Adu-Amankwaah, Francis
Tapfuma, Kudzanai Ian
Hussan, Raeesa Hoosen
Tshililo, Ndivhuwo
Baatjies, Lucinda
Masiphephethu, Maano Valerie
Mabasa, Lawrence
Mavumengwana, Vuyo
SOUTH AFRICAN JOURNAL OF BOTANY, 2022, 150 : 702 - 710
[28] Asporin: The protective wall against triple-negative breast cancer
Blomme, Arnaud
Cusumano, Pino
Peulen, Olivier
Bellahcene, Akeila
Castronovo, Vincent
Turtoi, Andrei
M S-MEDECINE SCIENCES, 2016, 32 (11): : 1019 - 1022
[29] Rational combination therapy against triple-negative breast cancer
Al-Ejeh, F.
Miranda, M.
Simpson, P. T.
Chenevix-Trench, G.
Lakhani, S. R.
Khanna, K. K.
CANCER RESEARCH, 2012, 72
[30] Ruthenium metallodendrimer against triple-negative breast cancer in mice
Michlewska, Sylwia
Wojkowska, Dagmara
Watala, Cezary
Skiba, Elzbieta
Ortega, Paula
de la Mata, Francisco Javier
Bryszewska, Maria
Ionov, Maksim
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2023, 53

← 1 2 3 4 5 →